Figure 7

Promoter activities for EGF- or TNF-responsive CCL20 and CXCL8 in ovarian cancer cells. CCL20 promoter activity (A) and CXCL8 promoter activity (B) in response to EGF (E), TNF (T) or both (ET) ± inhibitors for IκB (BAY-11-7082, Bay 2 μM), Akt (LY294002, LY 2 μM) and Erk (PD98059, PD 10 μM) in OVCAR-3, SKOV-3, CaOV3 and TOV-21G cells. After transfection with CCL20 and CXCL8 luciferase vectors overnight, a luciferase assay was performed. Results were normalized to total protein concentrations and expressed as fold increases compared to controls. Different asterisks (*,**,***) indicate significantly increased differences (P ≤ 0.05) within each group by ANOVA and Tukey’s pairwise comparison. A number sign (#) indicates a significant decrease (P ≤ 0.05) compared to EGF and TNF (ET) measures in the absence of inhibitors, as calculated by Student’s t-test. Experiments were performed in triplicate and all data are shown as mean ± SEM.